Touchlight announced an agreement with University of Liverpool for the use of dbDNA in the development of a fully-personalised therapeuticneoantigen DNA vaccine for patients with non-small cell lung cancer.
INOVIO has entered into an agreement to expand its manufacturing partnership with the German contract manufacturer Richter-Helm BioLogics GmbH & Co. KG.
DNA vaccines can be used as targeted therapeutic vaccines to induce an immune response which can detect and destroy infectious diseases and potentially cancer